Geneva Partners, LLC Eli Lilly & CO Transaction History

Geneva Partners, LLC

$223 Million
Q1 2024

A detailed history of Geneva Partners, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Geneva Partners, LLC holds 8,258 shares of LLY stock, worth $7.83 Million. This represents 2.88% of its overall portfolio holdings.

Number of Shares

8,258

Previous 8,656 4.6%

Holding current value

$7.83 Million

Previous $5.05 Million 27.33%

% of portfolio

2.88%

Previous 2.8%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$592.2 - $792.28 $235,695 - $315,327	-398 Reduced 4.6%	8,258 $6.42 Million
Q4 2023 Jan 31, 2024	SELL	$525.19 - $619.13 $224,781 - $264,987	-428 Reduced 4.71%	8,656 $5.05 Million
Q3 2023 Oct 25, 2023	BUY	$434.7 - $599.3 $1.67 Million - $2.3 Million	3,839 Added 73.19%	9,084 $4.88 Million
Q2 2023 Aug 03, 2023	BUY	$350.74 - $468.98 $579,773 - $775,223	1,653 Added 46.02%	5,245 $2.46 Million
Q1 2023 Apr 26, 2023	SELL	$310.63 - $364.82 $154,693 - $181,680	-498 Reduced 12.18%	3,592 $1.23 Million

Q4 2022 Jan 23, 2023	BUY	$321.55 - $374.67 $1.32 Million - $1.53 Million	4,090 New	4,090 $0
Q2 2022 Jul 25, 2022	SELL	$278.73 - $327.27 $851,520 - $999,809	-3,055 Closed	0 $0
Q1 2022 May 03, 2022	BUY	$234.69 - $291.66 $364,942 - $453,531	1,555 Added 103.67%	3,055 $875,000
Q4 2021 Jan 31, 2022	BUY	$224.85 - $279.04 $337,275 - $418,560	1,500 New	1,500 $414,000
Q4 2020 Feb 01, 2021	SELL	$130.46 - $172.63 $3.92 Million - $5.19 Million	-30,075 Closed	0 $0
Q3 2020 Oct 28, 2020	SELL	$146.22 - $169.13 $59,950 - $69,343	-410 Reduced 1.34%	30,075 $4.45 Million
Q2 2020 Jul 20, 2020	BUY	$136.42 - $164.18 $743,488 - $894,781	5,450 Added 21.77%	30,485 $5.01 Million
Q1 2020 Apr 27, 2020	BUY	$119.05 - $147.35 $2.98 Million - $3.69 Million	25,035 New	25,035 $3.47 Million

Others Institutions Holding LLY

# of Institutions

3,729

Shares Held

738M

Call Options Held

9.09M

Put Options Held

7.22M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $901B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneva Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geneva Partners, LLC with notifications on news.

Account

Geneva Partners, LLC Eli Lilly & CO Transaction History